原发性硬化性胆管炎患者的肝胆恶性肿瘤监测
该研究回顾了1995至2015年梅奥诊所罗切斯特院区830例原发性硬化性胆管炎患者,其中79例发生肝胆恶性肿瘤。监测组5年总生存率显著高于非监测组(68% vs 20%,P<0.001),5年肝胆恶性肿瘤相关不良事件概率显著低于非监测组(32% vs 75%,P<0.001)。
要点
- 原发性硬化性胆管炎患者中,51%(40/79)发生肝胆恶性肿瘤者接受了监测,49%(39/79)未接受监测。
- 监测组5年总生存率68%,非监测组20%,差异显著(P<0.001)。
- 监测组5年肝胆恶性肿瘤相关不良事件概率32%,非监测组75%,差异显著(P<0.001)。
核心结论
- 本研究表明,肝胆恶性肿瘤监测显著改善了原发性硬化性胆管炎患者的结局,包括生存。
研究设计与样本
- 回顾性研究,审查了1995至2015年梅奥诊所罗切斯特院区原发性硬化性胆管炎患者的病历。
- 纳入随访≥1年且发生肝胆恶性肿瘤的患者,共79例(来自830例原发性硬化性胆管炎患者)。
- 根据监测状态(腹部影像、糖类抗原19-9、甲胎蛋白)对患者进行分类。
- 主要终点为肝胆恶性肿瘤复发、肝胆恶性肿瘤相关死亡和全因死亡率。
- 总生存采用Kaplan-Meier生存法评估,肝胆恶性肿瘤相关生存采用竞争风险回归评估;检验为双侧,P<0.05为统计学显著。
主要发现
- 79例发生肝胆恶性肿瘤的患者中,78%(54/79)发生胆管癌,21%(17/79)发生肝细胞癌,6%(5/79)发生胆囊癌,3%(2/79)同时发生胆管癌和肝细胞癌,1%(1/79)同时发生肝细胞癌和胆囊癌。
- 肝胆恶性肿瘤诊断前累计随访712人年,诊断后累计随访283人年。
- 监测组5年总生存率68%,非监测组20%,差异显著(P<0.001)。
- 监测组5年肝胆恶性肿瘤相关不良事件概率32%,非监测组75%,差异显著(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), remains unclear. We aimed to determine whether surveillance is associated with better survival after diagnosis of HBCa in patients with PSC. Medical records of PSC patients seen at the Mayo Clinic Rochester from 1995 to 2015 were reviewed. Patients were included if they had ≥1 year of follow-up and developed HBCa. Patients were categorized according to their surveillance status (abdominal imaging, carbohydrate antigen 19-9, and alpha-fetoprotein). The primary endpoints were HBCa recurrence, HBCa-related death, and all-cause mortality. Overall survival was assessed by the Kaplan-Meier survival method; HBCa-related survival was assessed using competing risk regression. Tests of significance were two-tailed, and a P value <0.05 was considered statistically significant. From 1995 to 2015, a total of 79 of 830 PSC patients were diagnosed with HBCa. Cumulative follow-up was 712 and 283 person-years pre- and post-HBCa diagnosis, respectively. Seventy-eight percent of patients (54/79) developed CCA, 21% (17/79) HCC, 6% (5/79) GBCa, 3% (2/79) both CCA and HCC, and 1% (1/79) both HCC and GBCa. Fifty-one percent (40/79) were under HBCa surveillance, and 49% (39/79) were not. Patients in the surveillance group had significantly higher 5-year overall survival (68% versus 20%, respectively; P < 0.001) and significantly lower 5-year probability of experiencing an HBCa-related adverse event (32% versus 75%, respectively; P < 0.001) compared with the no-surveillance group. CONCLUSION: This study demonstrates that HBCa surveillance significantly improves outcomes, including survival, in patients with PSC. (Hepatology 2018;67:2338-2351).
引用
- Ali AH, Tabibian JH, Nasser-Ghodsi N, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology. 2018. PMID: 29244227. doi:10.1002/hep.29730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。